Amyris Biotechnologies, Inc.

Amyris Commissions Commercial Production Facility at Tate & Lyle


Source: Amyris Biotechnologies, Inc.

Expands Production Capacity to Three Facilities in Three Countries

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Amyris, Inc. (NASDAQ:AMRS) announced the commissioning of its third industrial-scale facility for the production of Biofene®, Amyris’s renewable farnesene. The production facility is located in Decatur, Ill., at a facility owned by Tate & Lyle Ingredients Americas, Inc., an affiliate of Tate & Lyle PLC (LSE: TATE).

Amyris plans to sell Biofene directly for use in industrial applications or to apply simple chemical finishing steps to Biofene to form a broad range of renewable products including squalane, base oil and finished lubricants and diesel.

“Our third commercial facility – our first in the United States – will help us ramp up Biofene production volume to meet the strong worldwide demand we expect for our renewable products,” said John Melo, CEO of Amyris. “Commissioning this facility is also an affirmation of our commitment to developing manufacturing capacity in the United States and supporting job creation in the Midwest.”

“The timely and efficient commissioning of the production facility is a tribute to Tate & Lyle’s commercial skills and broad bio-based products experience,” said Matt Wineinger, president of Tate & Lyle Bulk Ingredients. “Our expertise, combined with Amyris’s innovative industrial synthetic biology, proves that sustainable alternatives can have both environmental and economic benefits.”

Amyris is scaling its production in Brazil, Europe and the United States through five production arrangements, including manufacturing agreements with Antibióticos S.A., Biomin do Brasil Nutri?ão Animal Ltda., Paraíso Bioenergia S.A., Tate & Lyle and a joint venture with Usina São Martinho S.A., one of the largest sugar and ethanol producers in Brazil. Amyris has also established finishing capabilities with Glycotech, Inc. in North Carolina.

About Amyris, Inc.

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules - flexible building blocks that can be used in a wide range of products. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil Ltda., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels, LLC. More information about Amyris is available at

About Tate & Lyle

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, operating from over 30 production facilities around the world. Tate & Lyle operates through two global business units, Speciality Food Ingredients and Bulk Ingredients, supported by Innovation and Commercial Development. The Group's strategy is to become the leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving the Bulk Ingredients business for sustained cash generation to fuel this growth. Speciality Food Ingredients include starch-based specialty ingredients (corn-based specialty starches and sweeteners), SPLENDA® Sucralose (a high intensity sweetener made from sugar) and Food Systems which provides blended ingredient solutions. Bulk Ingredients include corn-based bulk sweeteners, industrial starches and fermentation products (primarily acidulants). The co-products from both divisions are primarily sold as animal feed. Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2011, Tate & Lyle sales totaled £2.7 billion. More information about Tate & Lyle is available at

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding the ramp on Amyris’s commercial-scale production volumes and anticipated demand for Amyris’s products) that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production or commercialization of products, our reliance on third parties to achieve our goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on March 14, 2011 and quarterly reports on Form 10-Q filed on May 11, 2011 and August 11, 2011. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.

SPLENDA® is a trademark of McNeil Nutritionals, LLC

Customer comments

No comments were found for Amyris Commissions Commercial Production Facility at Tate & Lyle. Be the first to comment!